Definiens Overview
- Year Founded
-
1994
- Status
-
Acquired/Merged
- Employees
-
140
- Latest Deal Type
-
M&A
- Financing Rounds
-
5
Definiens General Information
Description
Provider of an image analysis technology for digital pathology. The company provides image analysis and data mining products for quantitative digital pathology in the life sciences, diagnostic biomarkers and healthcare industries.
Contact Information
Website
www.definiens.comCorporate Office
- Bernhard-Wicki-Straße 5
- 80636 Munich
- Germany
Corporate Office
- Bernhard-Wicki-Straße 5
- 80636 Munich
- Germany
Definiens Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Definiens Comparisons
Industry
Financing
Details
Definiens Competitors (19)
One of Definiens’s 19 competitors is microDimensions, a Formerly VC-backed company based in Cloppenburg, Germany.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| microDimensions | Formerly VC-backed | Cloppenburg, Germany | ||||
| Judi | Formerly Angel backed | Boston, MA | ||||
| Indica Labs | Venture Capital-Backed | Albuquerque, NM | ||||
| Visiopharm | Private Equity-Backed | Hoersholm, Denmark | ||||
| Medic Vision Imaging Solutions | Venture Capital-Backed | Tirat Carmel, Israel |
Definiens Patents
Definiens Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20190252075-A1 | Predicting prostate cancer recurrence using a prognostic model that combines immunohistochemical staining and gene expression profiling | Inactive | 12-Feb-2018 | ||
| US-10438096-B2 | Identifying and excluding blurred areas of images of stained tissue to improve cancer scoring | Active | 27-Dec-2016 | ||
| US-20180182099-A1 | Identifying and excluding blurred areas of images of stained tissue to improve cancer scoring | Active | 27-Dec-2016 | ||
| EP-3538142-A1 | Anti-pd-l1 and anti-ctla-4 antibodies for treating non-small cell lung cancer | Inactive | 11-Nov-2016 | ||
| EP-3538142-A4 | Anti-pd-l1 and anti-ctla-4 antibodies for treating non-small cell lung cancer | Inactive | 11-Nov-2016 | G01N33/5752 |
Definiens Signals
Definiens Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Definiens FAQs
-
When was Definiens founded?
Definiens was founded in 1994.
-
Where is Definiens headquartered?
Definiens is headquartered in Munich, Germany.
-
What is the size of Definiens?
Definiens has 140 total employees.
-
What industry is Definiens in?
Definiens’s primary industry is Other Healthcare Technology Systems.
-
Is Definiens a private or public company?
Definiens is a Private company.
-
What is the current valuation of Definiens?
The current valuation of Definiens is .
-
What is Definiens’s current revenue?
The current revenue for Definiens is .
-
How much funding has Definiens raised over time?
Definiens has raised $45.7M.
-
Who are Definiens’s investors?
Bayern Kapital, Cipio Partners, Gilde Healthcare, LBBW Venture Capital, and Mercedes-Benz Group are 5 of 8 investors who have invested in Definiens.
-
Who are Definiens’s competitors?
microDimensions, Judi, Indica Labs, Visiopharm, and Medic Vision Imaging Solutions are some of the 19 competitors of Definiens.
-
When was Definiens acquired?
Definiens was acquired on 25-Nov-2014.
-
Who acquired Definiens?
Definiens was acquired by MedImmune.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process